Natural killer (NK) cells are a vital component of the innate immune response to virus-infected cells.
. However, using HIV-1 infected primary T-cells as target cells in NK cell functional assays has been difficult due the presence of contaminating uninfected cells 3 . This inconsistent infected cell to uninfected cell ratio will result in variation in NK cell killing between samples that may not be due to variability in donor NK cell function. Thus, it would be beneficial to work with a purified infected cell population in order to standardize the effector to target cell ratios between experiments 3, 4 . Here we demonstrate the isolation of a highly purified population of HIV-1 infected cells by taking advantage of HIV-1's ability to down-modulate CD4 on infected cells and the availability of commercial kits to remove dead or dying cells [3] [4] [5] [6] . The purified infected primary T-cell blasts can then be used as targets in either a degranulation or cytotoxic assay with purified NK cells as the effector population [5] [6] [7] . Use of NK cells as effectors in a degranulation assay evaluates the ability of an NK cell to release the lytic contents of specialized lysosomes 8 called "cytolytic granules". By staining with a fluorochrome conjugated antibody against CD107a, a lysosomal membrane protein that becomes expressed on the NK cell surface when the cytolytic granules fuse to the plasma membrane, we can determine what percentage of NK cells degranulate in response to target cell recognition. Alternatively, NK cell lytic activity can be evaluated in a cytotoxic assay that allows for the determination of the percentage of target cells lysed by release of 51 Cr from within the target cell in the presence of NK cells.
14. The supernatant is aspirated and the pellet is then resuspended in 10 mLs of RPMI-1640 medium (HyClone) containing 10% FBS, 100 U/ml of penicillin, 100 mcg/ml of streptomycin (HyClone) and 2 mM L-glutamine (CellGro) (RPMI-complete) and counted using a hemocytometer. 15. The concentration of purified CD4+ T-Cells is then adjusted to 3x10 6 /mL with RPMI-complete. 16. CD4+'s are then stimulated by culturing them with anti-CD3/anti-CD28 coupled to beads [T-Cell Expansion Kit (Miltenyi Biotec)] at a three beads per cell ratio for 72 hours at 37°C in a 5% C0 2 humidified incubator. Figure 1) 1. Cell suspension containing stimulated CD4+ T-Cells are removed from the culture plate and counted using a hemocytometer. 2. CD4+ T-cells (~2x10 6 ) are added to a 15 mL conical tube for use as an uninfected control. 3. The remainder of the CD4+ T-cell suspension is placed into a 50 mL conical tube for infection. 4. The tubes containing the CD4+ T-cell suspensions are centrifuged at 300 x g for 10 minutes and the culture supernatant is aspirated. 5. Stimulated CD4+ T-Cells are resuspended directly in culture fluids containing virions and then spin-infected at 1200 x g for 2 hours at 20-25°C 9 . Typically we infect CD4+ T-cells at a multiplicity of infection (MOI) of 5 for a replication deficient HIV strain (e.g., DHIV-3) or an MOI of 0.01 for a replication competent virus (e.g., HIV-1 NL4/3 ). Final volume is unimportant but tubes must be balanced for centrifugation. Polybrene (Santa Cruz) is added to the culture fluid prior to spinfection at a final concentration of 10 mcg/ml. 6. Upon completion of the spinfection, supernatants are removed and cells resuspended at a cell density of 3x10 6 /mL in RPMI-complete supplemented with 100 U/mL IL-2. The infected and uninfected cells are culture for 72 hours if a replication incompetent virus was used to infect the cell or 5-7 days if a replication competent virus was used to infect the cells. Media should be changed every 48 hours during culture. with the brake off. 5. The tubes are carefully removed from the centrifuge and the resulting interface between the LSM and medium is harvested from each tube using a 10 mL pipette and placed into fresh 50 mL conical tubes. 6. The cell suspensions are washed once with CMF HBSS (centrifuged at 400 x g for 15 minutes with the brake on). 7. After the first wash the supernatants are removed and the resulting pellets are combined into a single 50 mL conical and washed twice with CMF HBSS (centrifuged at 30 x g for 10 minutes with the brake on) to remove all remaining LSM. 8. After the last wash the pellet is resupended in 10 mL of ACK lysis buffer (150 mM NH 4 Cl, 1.0 mM KHCO 3 and 0.1 mM EDTA pH 7.3) and incubated at room temp (20-25°C) for 5 mins. This step is necessary in order to remove contaminating erythrocytes from the peripheral blood mononuclear cells (PBMC). 9. After 10 mins. 40 mL of CMF PBS is added to the cell suspension in order to stop the lysis reaction. 10. The tube with the cell suspension containing the PBMC and lysed erythrocytes is then centrifuged at 300 x g for 10 minutes with the brake on. 11. The supernatant is removed and the pellet is resuspended in 5 mL of PBS with 2% FBS and 2 mM EDTA and counted using a hemocytometer. 12. The natural killer (NK) cells are then isolated from the PBMC using an NK Cell Isolation Kit [negative selection-human (Miltenyi Biotec)] according to the manufacturers instructions. 13. The flow-through from the columns are collected in 15ml tubes and the tubes are centrifuged at 300 x g for 10 minutes with the brake on. 14. The supernatants are removed and the pellets resuspended. The resuspended pellets are combined in one tube in a total volume of 1 mL of Iscove's Modified Dulbecco's Medium [IMDM (Gibco)] supplemented with 10% AB+ heat inactivated (56°C for 30 minutes) human serum (HS) and counted with a hemacytometer. 15. The volume of cell suspension is adjusted with IMDM w/10% HS so that the final density of NK cells is 3x10 4. Cell suspensions from the isolated infected and uninfected T-cells generated in the above steps are centrifuged at 300 x g for 10 minutes with the brake on. 5. Supernatants are removed and pellets resuspended in RPMI-complete at 2x10 6 cells/mL.
Infection of CD4+ T-Cells with HIV-1 (see
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6. K562 cells are used as positive control target cells, as they are highly susceptible to NK lysis. The cells are centrifuged at 300 x g for 10 minutes with the brake on, supernatants are removed and pellets resuspended in RPMI-complete at 2x10 6 cells/mL 7. In a 96-v-bottomed well plate 100 mcL of targets and 100 mcL effectors are added to the wells. 8. A well containing 100 mcLof effectors and 100 mcL of medium without target cells will be used for non-specific NK cell degranulation. 9. To each well 10 mcLFITC-conjugated anti-CD107a (BDIS) is added. 10. The plate is then centrifuged at 20 x g for 2 minutes with the brake on. 11. The centrifuged plate is incubated for 4 hours at 37°C and 5% CO 2 . 12. After incubation the plate is centrifuged at 400 x g for 5 minutes with the brake on. 10. 100 mcL of the above NK cell suspensions are added to each well containing target cells. 11. 100 mcL of targets are added to corresponding wells in which effector cells are absent for the maximum and spontaneous release groups. The spontaneous release group is incubated with an additional 100 mcL of RPMI-complete. 12. The 96-well plate is centrifuged at 20 x g for 2 minutes with the brake on. 13. The centrifuged plate is then incubated at 37°C and 5% CO 2 for 4 hours. 14. After the 4-hour incubation 5 mcL of a 1:10 dilution of human red blood cells in RPMI-complete is added to each well except the maximum release wells. 15. 100 mcL of 10% sodium dodecyl sulfate is added to the maximum release wells. 16. The plate is centrifuged at 400 x g for 5 minutes to pellet the cells. Cr release assay at different effector cell to target cell ratios (E:T).
Discussion
When done correctly the assays described in this protocol should provide a representative picture of NK cells ability to degranulate against and lyse HIV-1 infected cells (see Figure 5 ). NK cell degranulation in response to HIV-infected cells and the NK cells lysis HIV-infected cells should be directly proportional 10 . Reliable results for the two NK cell functional assays to measure cytotoxic responses to HIV-infected cells are dependant on the isolation of highly purified NK cells as well as a highly purified population of infected cells. Having purified NK cells and HIV-1 infected cells are critical for the achievement of a fairly accurate effector to target cell ratio. Similarly, removal of dead and apoptotic cells from the target cell populations is important before 51 Cr labeling or incubation with the effector cells.
51
Cr may be internalized by cells that are undergoing apoptosis as the presence of dead or apoptotic cells during the isotope labeling step will result in a high spontaneous release and will distort the calculated % specific lysis. Moreover, the presence of dead or apoptotic cells may trigger NK cell degranulation resulting in abnormally high levels of CD107a expression. Precise pipetting is necessary when removing the cell-free supernatants following the incubation of NK cells and target cells in the 51 Cr release assays, as differences in the volume of supernatant removed from each replicate well will result in high standard deviations. Modifications can be made to these protocols to evaluate the role of specific NK receptors in triggering NK cells lysis of HIV-infected cells by incubating the effectors or targets prior to co-culture with antagonistic antibodies to specific receptors or ligands 6, 11 . Cytokine-treated NK cells (e.g., IL-2, IL-15) can be used to evaluate the functionality of stimulated NK cells 12 . Similarly, antibody dependant cell cytotoxicity assays may be performed using these protocols. Anti-HIV antibodies (e.g., anti-gp120) can be added to the target cells for recognition by the NK cell low affinity Fc receptor CD16 13 . These assays, although set up to measure NK cell cytotoxic responses to HIVinfected cells, can also be modified to measure the ability of NK cells to produce cytokines following HIV-infected cell recognition. Although we described in this protocol the use of in vitro infected cells as target cells we have recently described the generation of target cells from patients infected with HIV. This requires the isolation of CD4+ T-cells followed by expansion of the cells over a two week period following stimulation with mitogens in the presence of interleukin-2 11 . After the two week period of expansion, the protocols described in this article are used to isolate the target cells.
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